Verona Pharma Plc
(NASDAQ : VRNA)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Are you a Dividend Trader
Learn how to make passive income from the best dividend stocks.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Other
symbolcompany%chnglast%shortavg$volume
VRXValeant Pharmaceuticals International, Inc. 1.71%30.2614.1%$178.05m
AMRNAmarin Corp. Plc -0.75%19.911.7%$159.55m
AXSMAxsome Therapeutics, Inc. -2.31%90.341.9%$129.63m
SAVACassava Sciences, Inc. -4.40%8.250.0%$91.12m
ARQLArQule, Inc. 0.15%20.000.6%$78.96m
BHCBausch Health Cos., Inc. 1.71%30.260.0%$74.96m
SAGESAGE Therapeutics, Inc. 3.12%76.408.6%$70.78m
GWPHGW Pharmaceuticals Plc -0.13%118.976.2%$70.43m
JAZZJazz Pharmaceuticals Plc -0.36%151.052.3%$67.88m
ICPTIntercept Pharmaceuticals, Inc. -3.76%106.1116.9%$63.50m
PRGOPerrigo Co. Plc -0.82%59.026.8%$58.61m
HZNPHorizon Therapeutics Plc 0.29%38.406.6%$57.70m
ENDPEndo International Plc -2.27%6.048.8%$42.46m
ICLRICON plc 0.38%175.784.2%$41.39m
CTLTCatalent, Inc. -1.03%60.842.4%$37.19m

Company Profile

Verona Pharma Plc operates as a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for the treatment of respiratory diseases. It's product include, RPL554, is a dual inhibitor of the enzymes phosphodiesterase 3 and 4 that acts as both a bronchodilator and an anti-inflammatory agent in a single compound. The firm develops RPL554 for the treatment of chronic obstructive pulmonary disease (COPD), cystic fibrosis, and potentially asthma. The company was founded by Michael J. A. Walker and Clive P. Page on February 24, 2005 and is headquartered in London, United Kingdom.